Argenx Se (ARGX) Short-term Investments (2015 - 2025)
Argenx Se (ARGX) posted Short-term Investments of $948.8 million for Q4 2025, down 99.95% on a QoQ basis from $1842.2 billion in Q2 2025, and down 49.5% year-over-year from $1.9 billion in Q4 2024.
Argenx Se (ARGX) Short-term Investments (2015 - 2025) Analysis & Trends
Argenx Se's Short-term Investments history runs 11 years deep, the most recent figure standing at $948.8 million for Q4 2025.
- Quarterly Short-term Investments fell 49.5% year-over-year to $948.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $948.8 million (down 49.5% YoY) and the FY2025 annual result came in at $2.4 billion, up 209.38% from the prior year.
- Short-term Investments was $948.8 million for Q4 2025 at Argenx Se, down from $1842.2 billion in the prior quarter.
- Across five years, Short-term Investments topped out at $1842.2 billion in Q2 2025 and bottomed at -$1108.4 billion in Q2 2024.
- A 5-year average of $74.3 billion and a median of $1.1 billion in 2021 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments tumbled 125146.11% — and 2025, when it soared 266.2%.
- Argenx Se's Short-term Investments stood at $1.0 billion in 2021, then surged by 38.9% to $1.4 billion in 2022, then retreated by 18.74% to $1.1 billion in 2023, then soared by 66.13% to $1.9 billion in 2024, then plunged by 49.5% to $948.8 million in 2025.
- Business Quant data shows ARGX's Short-term Investments at $948.8 million in Q4 2025, $1842.2 billion in Q2 2025, and $1.9 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 948.75 Mn |
| Jun 30, 2025 | 1,842.20 Bn |
| Dec 31, 2024 | 1.88 Bn |
| Jun 30, 2024 | -1,108.41 Bn |
| Dec 31, 2023 | 1.13 Bn |
| Jun 30, 2023 | 886.40 Mn |
| Dec 31, 2022 | 1.39 Bn |
| Jun 30, 2022 | 1.23 Bn |
| Dec 31, 2021 | 1.00 Bn |
| Jun 30, 2021 | 1.15 Bn |
| Dec 31, 2020 | 757.53 Mn |
| Jun 30, 2020 | 805.56 Mn |
| Dec 31, 2019 | 1.11 Bn |
| Jun 30, 2019 | 872.49 Mn |
| Dec 31, 2018 | 323.62 Mn |
| Jun 30, 2018 | 236.28 Mn |
| Dec 31, 2017 | 198.88 Mn |
| Jun 30, 2017 | 107.64 Mn |
| Dec 31, 2016 | 7.38 Mn |
| Dec 31, 2015 | 7.47 Mn |